This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Jefferies Keeps Their Buy Rating on Corteva (CTVA)
In a report released today, from Jefferies maintained a Buy rating on Corteva, with a price target of $97.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
In addition to Jefferies, Corteva also received a Buy from Bank of America Securities’s Matthew DeYoe in a report issued today. However, on June 9, UBS assigned a Hold rating to Corteva (NYSE: CTVA).
Based on Corteva’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $4.91 billion and a net profit of $720 million. In comparison, last year the company earned a revenue of $4.42 billion and had a net profit of $652 million
Read More on CTVA:
Disclaimer & DisclosureReport an Issue
- Corteva: Buy Rating Reaffirmed as Analyst Lifts Price Target to $95 on Solid Near-Term Outlook and Upside Potential
- FMC, Corteva announce co-exclusive rimisoxafen supply and license pact
- Corteva to cease production activities at site in Asturias, Spain
- Corteva price target raised to $91 from $84 at Barclays
- Corteva price target lowered to $86 from $90 at UBS
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
